Thank you for sharing!

Your article was successfully shared with the contacts you provided.
CLASS ACTION the clinical laboratory Quest Diagnostics has agreed to settle a class action challenging its procedures in screening for Tay-Sachs disease, a fatal genetic disorder common to persons of Eastern European Jewish ancestry. While continuing to deny liability, Quest (a successor in interest to MetPath and MetWest and Corning Clinical Laboratories) has agreed to pay $600,000 to the class, comprised of people tested between November 1992 and December 1998. In certain cases, Quest will also retest persons who were previously screened. Proofs of claim must be filed no later than August 7. Stevens v. Quest Diagnostics Inc., No. 19496/00 (Kings Co., N.Y., Sup. Ct. April 8). FOR PLAINTIFFS: David Jaroslawicz, Jaroslawicz & Jaros, New York FOR DEFENDANT: William I. Sussman, Reboul MacMurray Hewitt & Maynard, New York. Source:

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.